Torres AO, Olvera GC, Terrés TF, Aguirre SJ, Franco GJ

Idioma: Español
Referencias bibliográficas: 31
Paginas: 118-124
Archivo PDF: 187.98 Kb.

RESUMEN

El síndrome de choque tóxico es una condición crítica que se presenta por la respuesta inmunológica del huésped ante un grupo limitado de agentes patógenos. Su patogénesis es compleja e involucra factores antigénicos propios de la bacteria y mediadores inflamatorios del huésped. El tratamiento del síndrome de choque tóxico debe basarse en la evidencia actual más fuerte, puede llegar a ser un desafío y requiere un diagnóstico oportuno. Se presenta el caso clínico de un paciente de la Unidad de Medicina Crítica que desarrolla síndrome de choque tóxico a partir de una infección de tejidos blandos en la región perianal. El tratamiento del paciente involucró medidas para controlar la falla orgánica múltiple en un contexto de choque. Finalmente el paciente presentó complicaciones que provocaron la pérdida de estructuras anatómicas distales a pesar de un intenso y adecuado tratamiento que fue pauta para frenar el síndrome a una progresión fatal. El objetivo de esta revisión es hacer énfasis en la importancia del diagnóstico y tratamiento temprano, ya que no suele ser una patología frecuente en nuestro medio.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet. 1978; 2 (8100): 1116-1118.

2. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980; 303 (25): 1436-1442.

3. Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980; 303 (25): 1429-1435.

4. Massell BF, Chute CG, Walker AM, Kurland GS. Penicillin and the marked decrease in morbidity and mortality from rheumatic fever in the United States. N Engl J Med. 1988; 318 (5): 280-286.

5. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis. 1989; 11 (6): 928-953.

6. Wolf JE, Rabinowitz LG. Streptococcal toxic shock-like syndrome. Arch Dermatol. 1995; 131 (1): 73-77.

7. Margolis DJ, Horlick SE. Group A streptococcus-induced bullous toxic shock-like syndrome. J Am Acad Dermatol. 1991; 24 (5 Pt 1): 786-787.

8. Kellum JA. KDIGO clinical practice guideline for acute kidney injury. Kidney International [consulta 29/06/15]. Available in: http://kdigo.org/home/guidelines/acute-kidney-injury/

9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41 (2): 580-637.

10. Low DE. Toxic shock syndrome: major advances in pathogenesis, but not treatment. Crit Care Clin. 2013; 29 (3): 651-675.

11. Eriksson BK, Andersson J, Holm SE, Norgren M. Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis. 1998; 27 (6): 1428-1436.

12. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis. 1992; 14 (1): 2-11.

13. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321 (1): 1-7.

14. Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schalén C et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007; 45 (4): 450-458.

15. Lepoutre A, Doloy A, Bidet P, Leblond A, Perrocheau A, Bingen E et al. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol. 2011; 49 (12): 4094-4100.

16. O’Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007; 45 (7): 853-862.

17. Ekelund K, Skinhøj P, Madsen J, Konradsen HB. Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. J Clin Microbiol. 2005; 43 (4): 1789-1796.

18. O’Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM et al. Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis. 2002; 35 (3): 268-276.

19. Haywood CT, McGeer A, Low DE. Clinical experience with 20 cases of group A streptococcus necrotizing fascitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg. 1999; 103 (6): 1567-1573.

20. Johansson L, Thulin P, Low DE, Norrby-Teglund A. Getting under the skin: the immunopathogenesis of Streptococcus pyogenes deep tissue infections. Clin Infect Dis. 2010; 51 (1): 58-65.

21. Johansson L, Linner A, Sunden-Cullberg J, Haggar A, Herwald H, Loré K et al. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. J Immunol. 2009; 183 (6): 4047-4054.

22. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014; 370 (10): 1412-1421.

23. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998; 64 (5): 397-400.

24. Vieillard-Baron A. Septic cardiomyopathy. Ann Intensive Care. 2011; 1 (1): 6.

25. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007; 38 Suppl. 5: S19-26.

26. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology and determinants of mortality. J Bone Joint Surg Am. 2003; 85-A (8): 1454-1460.

27. Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014; 59 (3): 358-365.

28. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59 (2): e10-52.

29. Berlot G, Rossini P, Turchet F. Biology of immunoglobulin’s. Transl Med UniSa. 2014; 11: 24-27.

30. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999; 28 (4): 800-807.

31. Linner A, Darenberg J, Sjolin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome a comparative observational study. Clin Infect Dis. 2014; 59 (6): 851-857.